Английская Википедия:Amyris, Inc.

Материал из Онлайн справочника
Версия от 14:39, 30 января 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|American biotechnology company}} {{Infobox company | name = Amyris, Inc. | logo = Wiki-Amyris Purple.png | type = Public | traded_as = {{OTC Pink|AMRSQ}}<br>{{NASDAQ was|AMRS}} | foundation = 2003 | location = Emeryville, California, US | industry = Renewable fuels, antimalarials, renewable chemicals, renewable p...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Infobox company Amyris, Inc. is a synthetic biotechnology and renewable chemical company headquartered in Emeryville, California. Amyris serves the specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals markets.[1]

History

Amyris was founded in 2003.[2] The company owns three brands, Biossance and Pipette, for beauty and skincare, and Purecane, a sugar substitute. The company went public on NASDAQ on September 28, 2010 (AMRS).[3]

In November 2011, Amyris acquired Lansing, Michigan-based renewable chemicals and products company, Draths Corporation, for $7 million in stock.[4] ATEL Capital Group acquired a stake in Amyris in December 2011.[5] In January 2016, the company received an investment from the Bill & Melinda Gates Foundation's Strategic Innovation Fund to support the development of antimalarial medication based on semi-synthetic artemisinin.[6] In April 2019, the company raised $34-million in private placement of its common stock and warrants. The funding round was led by Foris Ventures and Dr. Wei-wu He, General Partner of Emerging Technology Partners, LLC, a life sciences-focused venture fund.[7]

Biossance, the skincare brand from Amyris, was recognized as Digital Innovator of the Year at the WWD Beauty Inc Awards in 2019.[8]

In 2020, Amyris received Bonsucro's Chain of Custody Certification, ensuring that the sustainability claims along the sugarcane supply chain are traceable from farmer to end user.[9] During the COVID-19 pandemic, the company collaborated with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine.[10]

On August 9, 2023, Amyris filed for Chapter 11 bankruptcy protection and announced it will shut down its consumer brands amongst selling itself.[11] The company was delisted from Nasdaq and added to the OTC Markets.

References

Шаблон:Reflist

External links

Шаблон:Authority control